Registry for patients receiving a cancer detection test
Official title: Falcon - The Exact Sciences Multicancer Early Detection (MCED) Real World Evidence (RWE) Registry
Run by Exact Sciences Corporation · NCT06589310 · Data updated 2026-11-12
This study is creating a registry of patients who will take a new cancer detection test each year for three years to see how it helps with early cancer diagnosis and to compare their experiences with those who don’t take the test.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 50 Years to 80 Years |
| Sex | All |
| Enrollment | 25000 (estimated) |
| Sponsor | Exact Sciences Corporation Industry-sponsored |
| Drugs / interventions | chemotherapy, immunotherapy, radiation |
| Locations | 2 sites (Evanston, Illinois and 1 other locations) |
| Status | Recruiting |
| Started | August 1, 2024 |
| Main results expected | August 2030 |
| Study ends | January 2031 |
| Registry record updated | September 11, 2026 |
| Trial ID | NCT06589310 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals aged 50 to 80 who are willing to undergo the MCED test and provide informed consent.
✕Probably not a fit
Patients with a history of invasive tumors or current cancer suspicion will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to create a multi-site registry of patients who will receive the Exact Sciences Multicancer Early Detection (MCED) test annually for three years. Participants will be monitored for cancer diagnoses, and data will be collected for five years following their initial test. The study will gather self-reported data on the testing experience and extract data from existing electronic health records for comparison with individuals who did not receive the MCED test.
Why it matters
Potential benefit: If successful, this study could enhance early cancer detection and improve patient outcomes through better screening practices.
How similar studies have gone: Other studies utilizing similar early detection approaches have shown promise, indicating potential for success in this registry.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participant age at time of consent is between 50 and 80 years * Agree to receive the Exact Sciences MCED test and follow-up imaging * Willing and able to provide informed consent * Access to a suitable technology and willing to complete surveys electronically Exclusion Criteria: * Any invasive tumor (excluding non-melanoma skin cancers) or hematological malignancy in the previous three years or current suspicion of cancer and/or in active treatment (e.g., chemotherapy, radiation therapy, immunotherapy, and/or surgery
Where it's running
-
Endeavor Health
Evanston, Illinois, United States Recruiting -
Baylor Scott & White Health
Dallas, Texas, United States Recruiting
Study contacts
- Principal investigator: Tomasz M Beer, MD — Exact Sciences
- Study coordinator: Emily Twomey
- Email: etwomey@exactsciences.com
- Phone: 608-640-7143
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Detection of molecular residual disease in breast cancer patients
This study is testing if checking for cancer DNA in blood and tissue samples can help doctors better manage treatment for women with high-risk, early breast cancer starting chemotherapy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.